Research & Development

Sanofi to acquire mRNA partner Translate Bio for $3.2bn

Sanofi has agreed to acquire a mRNA therapeutics firm Translate Bio to advance the use of messenger RNA (mRNA) technology across vaccines and therapeutics development.

Ipsen, Exicure to co-develop therapies for neurodegenerative diseases

Biopharmaceutical company Ipsen and Exicure have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational therapies to treat Angelman syndrome and Huntington’s disease.

Takeda, Frazier to launch HilleVax for norovirus vaccine development

Takeda Pharmaceutical has announced collaboration with Frazier Healthcare Partners to launch HilleVax to develop and commercialise the former’s clinical stage norovirus vaccine candidate, HIL-214 (formerly TAK-214).

Deep Genomics raises $180m funding to expand AI platform for RNA therapies

Deep Genomics has raised $180m funding in Series C financing round to expand its artificial intelligence (AI) discovery platform for ‘Programmable’ RNA therapeutics and scale its portfolio into the clinic.

AbbVie, Calico extend collaboration to develop new age-related disease therapies

AbbVie has extended its collaboration with Calico Life Sciences to discover and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer.

Amgen to acquire clinical stage biotechnology firm Teneobio

Biotechnology company Amgen has agreed to acquire Teneobio, a privately held clinical stage biotechnology firm, in a deal valued at about $900m.

PerkinElmer to acquire life science antibodies provider BioLegend for $5.25bn

PerkinElmer has signed an agreement to acquire US-based BioLegend, a life science antibodies and reagents provider, in a deal valued at about $5.25bn.

Pfizer and Arvinas to jointly develop and commercialise breast cancer drug

Pfizer and Arvinas have collaborated to co-develop and co-commercialise ARV-471, an investigational oral Protac estrogen receptor protein degrader.

Three US drug distributors agree to pay $1.18bn to settle opioid case in New York

McKesson Corporation, Cardinal Health and Amerisource Bergen Drug, the three largest US drug distributors, have agreed to pay up to $1.18bn to settle the ongoing opioid-related case with the New York State and its participating subdivisions Nassau County and Suffolk County.